Immutep

Immutep develops T-cell response-based immunotherapeutics against cancer and infectious diseases.







» Corporate Information
© 2002 Immutep, S.A.
Press Release
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...
10/2009 - New results confirm that ImmuFact IMP321 doubles clinical response rate
image Immutep S.A. announced today interim results from the first three ...
09/2009 - Clinical research paper describes IMP321’s potency in inducing progression-free survival improvement and effector memory T cells
image Immutep S.A. announced today the publication of a clinical research ...
04/2009 - A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer has started at Washington University in Saint Louis (MO)
image Immutep S.A. announced today the first administration of IMP321 in ...
01/2009 - ImmuFact IMP321 associated with paclitaxel doubles clinical response rate
image Immutep S.A. announced today interim results from its ongoing Phase ...